View Financial HealthAnbio Biotechnology 배당 및 자사주 매입배당 기준 점검 0/6Anbio Biotechnology 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-0.7%자사주 매입 수익률총 주주 수익률-0.7%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updatesNew Risk • Jun 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 3.4% per year over the past 5 years. High level of non-cash earnings (111% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (11% average weekly change).Board Change • May 20High number of new directorsIndependent Director Michael Zhang was the last director to join the board, commencing their role in 2026.공시 • Jan 27Anbio Biotechnology Announces Board and Committee Changes, Effective January 21, 2026Effective January 21, 2026, as approved by the Board of Directors, the Nominating Committee and the Compensation Committee of Anbio Biotechnology, Michael Zhang was appointed as a director, the Chair of Audit Committee, a member of Nominating Committee and a member of Compensation Committee. Michael Zhang would replace Kenneth Li as a director, the Chair of Audit Committee, a member of Nominating Committee and a member of Compensation Committee. Kenneth Li’s departure was not a result of any disagreement with the Company’s operations, policies or procedures. Michael Zhang has over 30 years’ experience in finance. He has worked as a managing partner, overseeing all corporate finance and investment-related matters at Healthcare Alpha Management since 2014. He obtained his bachelor’s degree in business from Indiana University Bloomington in 1996 and master’s degree in business administration from Yale University in 2004.Seeking Alpha • Oct 10Anbio Biotechnology's Hype And Hard Approvals Suggest A Stretched ValuationSummary Anbio Biotechnology is a medical device firm specializing in in-vitro diagnostics, with recent stock volatility and a thin public float. I believe they continue to face significant regulatory hurdles in both the EU (IVDR transition) and the US (FDA clearance). Likewise, NNNN trades at an extremely high valuation relative to its fundamentals and peers. It also has concentrated voting control on Class B shares. Thus, agency risks, regulatory uncertainties, and an expensive valuation nudge me towards "Sell" on the stock. Read the full article on Seeking Alpha공시 • Oct 10Anbio Biotechnology Showcases Diagnostic Portfolio At WSAVA 2025Anbio Biotechnology participated in the 50th World Small Animal Veterinary Association Congress (WSAVA 2025), an international gathering that brought together veterinarians, researchers, and industry representatives from more than 100 countries. The event provided a platform for Anbio to present its veterinary diagnostic portfolio and exchange views with partners across global markets. At WSAVA 2025, Anbio displayed five product lines: Fluorescence Immunoassay (FIA); Dry Chemistry; Molecular Diagnostics; Colloidal Gold Rapid Tests; Dry Chemiluminescence Immunoassay (CLIA). The portfolio generated interest among veterinarians, distributors, and industry participants. The dry chemistry and fluorescence immunoassay systems were noted for their precision and usability, while discussions with distributors reflected demand for accessible and accurate testing technologies in veterinary healthcare. A key feature was Anbio's molecular diagnostics platform, capable of producing multi-target real-time PCR results within 15 minutes. This function was highlighted as a practical option for the rapid detection of respiratory and infectious diseases in animals, where timely results are critical to clinical management. Delegates pointed to the relevance of such technologies in strengthening outbreak response and supporting routine diagnostic workflows. The exhibition also provided opportunities for Anbio to engage with existing and potential partners, discuss distribution strategies, and consider future product rollouts. These exchanges underlined the increasing role of point-of-care diagnostics in veterinary practice and emphasized the importance of international collaboration in expanding access to diagnostic tools. Looking ahead, Anbio will continue its global outreach. The company is scheduled to participate in the Wild West Vet Show 2025, taking place from October 15-18, 2025, in Reno, Nevada, USA. The exhibition will provide another opportunity to present its veterinary diagnostic portfolio. Anbio's participation in WSAVA 2025 reflects its continuing efforts in both human and veterinary diagnostics. By advancing practical and reliable testing solutions, the company contributes to improving healthcare outcomes in diverse settings worldwide.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 NNNN 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: NNNN 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Anbio Biotechnology 배당 수익률 vs 시장NNNN의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (NNNN)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.2%업계 평균 (Biotechs)2.4%분석가 예측 (NNNN) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 NNNN 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 NNNN 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 NNNN 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: NNNN 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/07 07:54종가2026/06/05 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Anbio Biotechnology는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
New Risk • Jun 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 3.4% per year over the past 5 years. High level of non-cash earnings (111% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (11% average weekly change).
Board Change • May 20High number of new directorsIndependent Director Michael Zhang was the last director to join the board, commencing their role in 2026.
공시 • Jan 27Anbio Biotechnology Announces Board and Committee Changes, Effective January 21, 2026Effective January 21, 2026, as approved by the Board of Directors, the Nominating Committee and the Compensation Committee of Anbio Biotechnology, Michael Zhang was appointed as a director, the Chair of Audit Committee, a member of Nominating Committee and a member of Compensation Committee. Michael Zhang would replace Kenneth Li as a director, the Chair of Audit Committee, a member of Nominating Committee and a member of Compensation Committee. Kenneth Li’s departure was not a result of any disagreement with the Company’s operations, policies or procedures. Michael Zhang has over 30 years’ experience in finance. He has worked as a managing partner, overseeing all corporate finance and investment-related matters at Healthcare Alpha Management since 2014. He obtained his bachelor’s degree in business from Indiana University Bloomington in 1996 and master’s degree in business administration from Yale University in 2004.
Seeking Alpha • Oct 10Anbio Biotechnology's Hype And Hard Approvals Suggest A Stretched ValuationSummary Anbio Biotechnology is a medical device firm specializing in in-vitro diagnostics, with recent stock volatility and a thin public float. I believe they continue to face significant regulatory hurdles in both the EU (IVDR transition) and the US (FDA clearance). Likewise, NNNN trades at an extremely high valuation relative to its fundamentals and peers. It also has concentrated voting control on Class B shares. Thus, agency risks, regulatory uncertainties, and an expensive valuation nudge me towards "Sell" on the stock. Read the full article on Seeking Alpha
공시 • Oct 10Anbio Biotechnology Showcases Diagnostic Portfolio At WSAVA 2025Anbio Biotechnology participated in the 50th World Small Animal Veterinary Association Congress (WSAVA 2025), an international gathering that brought together veterinarians, researchers, and industry representatives from more than 100 countries. The event provided a platform for Anbio to present its veterinary diagnostic portfolio and exchange views with partners across global markets. At WSAVA 2025, Anbio displayed five product lines: Fluorescence Immunoassay (FIA); Dry Chemistry; Molecular Diagnostics; Colloidal Gold Rapid Tests; Dry Chemiluminescence Immunoassay (CLIA). The portfolio generated interest among veterinarians, distributors, and industry participants. The dry chemistry and fluorescence immunoassay systems were noted for their precision and usability, while discussions with distributors reflected demand for accessible and accurate testing technologies in veterinary healthcare. A key feature was Anbio's molecular diagnostics platform, capable of producing multi-target real-time PCR results within 15 minutes. This function was highlighted as a practical option for the rapid detection of respiratory and infectious diseases in animals, where timely results are critical to clinical management. Delegates pointed to the relevance of such technologies in strengthening outbreak response and supporting routine diagnostic workflows. The exhibition also provided opportunities for Anbio to engage with existing and potential partners, discuss distribution strategies, and consider future product rollouts. These exchanges underlined the increasing role of point-of-care diagnostics in veterinary practice and emphasized the importance of international collaboration in expanding access to diagnostic tools. Looking ahead, Anbio will continue its global outreach. The company is scheduled to participate in the Wild West Vet Show 2025, taking place from October 15-18, 2025, in Reno, Nevada, USA. The exhibition will provide another opportunity to present its veterinary diagnostic portfolio. Anbio's participation in WSAVA 2025 reflects its continuing efforts in both human and veterinary diagnostics. By advancing practical and reliable testing solutions, the company contributes to improving healthcare outcomes in diverse settings worldwide.